 |
|
Argatroban tPA Stroke Study
Study Design and Results in the First Treated Cohort
Rebecca M. Sugg, MD;
Jennifer K. Pary, MD;
Ken Uchino, MD;
Sarah Baraniuk, PhD;
Hashem M. Shaltoni, MD;
Nicole R. Gonzales, MD;
Robert Mikulik, MD;
Zsolt Garami, MD;
Sandi G. Shaw, RN, BSN;
Dawn E. Matherne, MSN, FNP;
Lemuel A. Moyé, PhD;
Andrei V. Alexandrov, MD;
James C. Grotta, MD
Arch Neurol. 2006;63:1057-1062.
Background The benefit of intravenous recombinant tissue plasminogen activator (rtPA) in acute stroke is linked to clot lysis and artery recanalization. Argatroban is a direct thrombin inhibitor that safely augments the benefit of rtPA in animal stroke models. There are no human data on this combination.
Design We report the first phase of the Argatroban tPA Stroke Study, an ongoing prospective, open-label, dose-escalation, safety and activity study of argatroban and rtPA in patients with ischemic stroke. The primary outcome was incidence of intracerebral hemorrhage; secondary outcome, complete recanalization at 2 hours. After standard-dose intravenous rtPA administration, a 100-µg/kg bolus of argatroban followed by infusion of 1 µg/kg per minute for 48 hours was adjusted to a target partial thromboplastin time of 1.75 times that of the control group.
Results Fifteen patients (including 10 men) were enrolled, with a mean ± SD age of 61 ± 13 years. All patients had middle cerebral artery occlusions. Baseline median National Institute of Health Stroke Scale score was 14 (range, 4-25). The mean ± SD time from symptom onset to argatroban bolus administration was 172 ± 53 minutes. Symptomatic intracerebral hemorrhage occurred in 2 patients, including 1 with parenchymal hemorrhage type 2. Asymptomatic bleeding occurred in 1 patient and there was 1 death. Recanalization was complete in 6 patients and partial in another 4, and reocclusion occurred in 3 within 2 hours of rtPA bolus administration.
Conclusion The safety of low-dose argatroban combined with intravenous rtPA may be within acceptable limits, and its efficacy for producing fast and complete recanalization is promising, but a larger cohort of patients is required to confirm these preliminary observations.
Trial Registration clinicaltrials.gov Identifier: NCT00268762
Author Affiliations: Department of Neurology, University of Texas–Houston Medical School (Drs Sugg, Pary, Uchino, Shaltoni, Gonzales, Mikulik, Garami, Alexandrov, and Grotta and Mss Shaw and Matherne), and Coordinating Center, University of Texas School of Public Health (Drs Baraniuk and Moyé), Houston.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Antiplatelet Therapy and the Risk of Intracranial Hemorrhage After Intravenous Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke
Hallevi and Grotta
Arch Neurol 2008;65:575-576.
FULL TEXT
A Pilot Randomized Clinical Safety Study of Sonothrombolysis Augmentation With Ultrasound-Activated Perflutren-Lipid Microspheres for Acute Ischemic Stroke
Alexandrov et al.
Stroke 2008;39:1464-1469.
ABSTRACT
| FULL TEXT
Is Intra-Arterial Thrombolysis Safe After Full-Dose Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke?
Shaltoni et al.
Stroke 2007;38:80-84.
ABSTRACT
| FULL TEXT
Clinical Deterioration After Intravenous Recombinant Tissue Plasminogen Activator Treatment: A Multicenter Transcranial Doppler Study
Saqqur et al.
Stroke 2007;38:69-74.
ABSTRACT
| FULL TEXT
|
